Stock DIGN DIGNITANA AB
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Dignitana AB

Equities

DIGN

SE0002108001

Market Closed - Nasdaq Stockholm
Other stock markets
 05:29:29 03/05/2024 pm IST 		5-day change 1st Jan Change
1.6 SEK +0.31% Intraday chart for Dignitana AB +3.90% -26.61%
24/04 Dignitana AB Announces Chief Executive Officer Changes , Effective May 2, 2024 CI
04/04 Dignitana Raises SEK19 Million via Rights Issue of Shares MT

Strengths

  • Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

Weaknesses

  • The company has insufficient levels of profitability.
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
  • For the past year, analysts have significantly revised downwards their profit estimates.
  • Over the past four months, analysts' average price target has been revised downwards significantly.
  • The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Sector: Medical Equipment, Supplies & Distribution

1st Jan change Capi. Investor Rating ESG Refinitiv
DIGNITANA AB Stock Dignitana AB
-26.61% 10.44M -
SHOCKWAVE MEDICAL, INC. Stock Shockwave Medical, Inc.
+73.37% 12.39B
B-
PENUMBRA, INC. Stock Penumbra, Inc.
-17.09% 8.08B
C+
MASIMO CORPORATION Stock Masimo Corporation
+16.88% 7.25B
C-
GETINGE AB Stock Getinge AB
+3.57% 5.86B
B
JIANGSU YUYUE MEDICAL EQUIPMENT & SUPPLY CO., LTD. Stock Jiangsu Yuyue Medical Equipment & Supply Co., Ltd.
+11.77% 5.35B
D+
APT MEDICAL INC. Stock APT Medical Inc.
+29.65% 4.63B -
ASAHI INTECC CO., LTD. Stock Asahi Intecc Co., Ltd.
-17.74% 4.19B
B-
INARI MEDICAL, INC. Stock Inari Medical, Inc.
-35.26% 2.44B
C
SKAN GROUP AG Stock SKAN Group AG
+3.09% 2.07B -
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
-
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
  1. Stock Market
  2. Equities
  3. DIGN Stock
  4. Ratings Dignitana AB